OBJECTIVES The aim of this study was to analyze the incidence, impact, and predictors of cerebrovascular events (CVEs) in patients undergoing transcatheter aortic valve replacement (TAVR).
T ranscatheter aortic valve implantation (TAVR) is a valid option for symptomatic patients with aortic stenosis and deemed inoperable or at high risk for conventional surgery. TAVR has proved to be superior to medical treatment for inoperable patients and to be noninferior to surgery in selected high-risk patients (1, 2) . Despite worldwide growing experience, several TAVR-related issues remain unresolved and insufficiently explored.
Among these issues, cerebrovascular events (CVEs) are one of the most serious complications, potentially affecting patient survival, autonomy, and quality of life. CVEs before and after TAVR may be multifactorial and include embolic debris or thrombus, aortic dissection, hemodynamic instability, and bleeding. The randomized PARTNER (Placement of Aortic Transcatheter Valves) trial raised concern about higher stroke rates post-TAVR compared with medical therapy or surgical aortic valve replacement (1, 2) . In other reports, stroke rates range from 1.5% to 20% (3, 4) . The FRANCE-2 (French Aortic National CoreValve and Edwards-2) registry is the largest TAVR registry published thus far on consecutive patients (5) . We aimed to explore the incidence, timing, impact, and predictors of CVEs in this large cohort of patients. General anesthesia or conscious sedation were used according to the heart team's preference. Patients were treated with aspirin and clopidogrel before the procedure (aspirin alone before transapical or direct aortic approaches). Unfractionated heparin was given at the start of the procedure aiming at an activated clotting time of 200 to 300 s. After TAVR, long-term aspirin therapy (75 to 300 mg) was prescribed, and clopidogrel was prescribed for 1 to 6 months according to each center's policy. For patients taking warfarin, aspirin was added (75 to 300 mg) for 1 to 6 months according to each center's preference. Minor stroke: diagnosis as above with a modified Rankin Scale score <2 at 7 days post diagnosis or before discharge and National Institutes of Health Stroke Scale (NIHSS) score <3 above baseline at 7 days or before discharge and at 30-day assessment.
METHODS
Major stroke: modified Rankin Scale score >2 at 7 days or before discharge and NIHSS score >3 above baseline at 7 days or before discharge and at 30-day assessment.
If there was discordance between modified Rankin Scale score and NIHSS score determinations of major versus minor stroke, final adjudication was made by a qualified neurologist.
NEW-ONSET ATRIAL FIBRILLATION. After TAVR, patients stayed in an intensive care unit for at least 2 days and then were followed with 24-h electrocardiographic monitoring until discharge.
During the hospital monitoring, new-onset paroxysmal atrial fibrillation was defined as a new episode of atrial fibrillation lasting >30 s but <1 day. Newonset persisting atrial fibrillation was defined as a new episode of atrial fibrillation lasting >1 day.
During the outpatient clinic follow-up, new-onset persisting atrial fibrillation was defined as a new episode documented on 12-lead electrocardiography. Creatinine clearance <60 ml/min, % 9.6 7. Tchetche et al.
The follow-up modalities did not allow for identification of episodes of paroxysmal atrial fibrillation. 
RESULTS
PATIENT CHARACTERISTICS. The baseline characteristics of the study population are reported in Table 1 . Patients experiencing CVEs were older (84.7 AE 6 years vs. 82.6 AE 7.2 years; p < 0.001). There were significantly more women experiencing CVEs (59.1% vs. 48.6%; p ¼ 0.02). The patients without CVEs more frequently had chronic atrial fibrillation (7.6% vs. 0.8%; p ¼ 0.004). There was no other difference at baseline between both groups of patients.
Of note, a history of stroke, porcelain aorta, and peripheral vascular disease were, respectively, observed in 10%, 8%, and 28.5% of the population.
CEREBROVASCULAR EVENTS. Patients were followed for an average of 5.2 AE 4.7 months after TAVR (median, 4.3 months), and 13% were followed for at least 12 months. Of the cohort, 127 patients had a CVE (3.98% of the population). A total of 123 patients had 1 event, and 4 patients had 2 events (3 patients with 2 major strokes and 1 patient with 2 TIAs). During follow-up, 2.2% of the patients had a major stroke, 0.6% had a minor stroke, and 1.2% had a TIA. These events occurred shortly after the procedure: 2 days (range, 0 to 7 days) (Table 2, Figure 1) . Most of CVEs (48.5%) were diagnosed within 48 h after TAVR, whereas 36.9% occurred between 2 and 30 days and 14.6% after 1 month.
PROCEDURAL OUTCOME. Transfemoral access was used in 74.6% of the population, and 66.9% of the patients received ES or ESXT valves ( Table 3) 
FIGURE 1 Timing of Cerebrovascular Events
Number of days elapsed from the index procedure before the occurrence of a cerebrovascular event.
Stroke in the FRANCE-2 Registry valve embolization resolved by either retrieval or impaction in an extra-annular location.
POST-PROCEDURAL OUTCOME AND SURVIVAL.
The post-procedural outcome is detailed in Table 3 . 
DISCUSSION
The FRANCE 2 registry is, to our knowledge, one of the largest prospective registries exploring CVEs.
These events occur frequently and have a negative impact on the patient survival after TAVR. CVEs ¼ cerebrovascular events; ICU ¼ intensive care unit.
FIGURE 2 Kaplan-Meier Survival Curves
One-year survival of all-cause mortality in patients with and without a cerebrovascular event.
Tchetche et al. Tables 1 and 2 .
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self-expandable MCV valve during deployment.
Overall, there were no significant differences between transfemoral and transapical TAVR or between the MCV and ES valve. In this series, only 1 subsequent major stroke and 1 minor stroke were diagnosed.
CVEs are associated with an increased mortality. In Abbreviations as in Tables 1 and 4 .
Tchetche et al. 
